Welcome to our dedicated page for Palvella Therapeutics news (Ticker: PVLA), a resource for investors and traders seeking the latest updates and insights on Palvella Therapeutics stock.
Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company developing investigational topical therapies for serious, rare skin diseases and vascular malformations that currently have no FDA-approved treatments. News about Palvella often centers on progress across its QTORIN™ platform, including clinical trial milestones, regulatory designations, and pipeline expansion.
The company’s lead candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is being studied in the Phase 3 SELVA trial for microcystic lymphatic malformations and in the Phase 2 TOIVA trial for cutaneous venous malformations, with additional development planned in clinically significant angiokeratomas. Updates on these programs include topline clinical results, details on trial design, and commentary from investigators and company leadership on efficacy and safety findings.
Palvella also reports news on its second product candidate, QTORIN™ pitavastatin, for disseminated superficial actinic porokeratosis, including announcements of its selection as a new QTORIN-derived therapy and plans for Phase 2 clinical evaluation. Regulatory and grant-related news, such as FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations and Orphan Products Grant funding, provide additional context on how regulators view the unmet need in the company’s target indications.
Investors and observers following PVLA news can expect coverage of quarterly financial results, corporate updates, leadership appointments in areas like medical affairs and innovation, and participation in healthcare conferences. This news stream helps track how Palvella advances its investigational programs, manages its development priorities, and positions its QTORIN™ platform within the rare dermatologic disease landscape, while consistently noting that its product candidates remain investigational and unapproved.
Palvella Therapeutics (Nasdaq: PVLA) reported Q1 2026 results and a corporate update highlighting clinical progress and strengthened liquidity. Key items: FDA pre-NDA meeting granted for QTORIN rapamycin in microcystic lymphatic malformations (meeting expected Q2 2026) with NDA submission on track for H2 2026.
Company completed an upsized $230.0 million equity financing and held $261.9 million cash and short-term investments as of March 31, 2026. Multiple trials and presentations scheduled through 2027; European patent issued covering compositions through 2038.
Palvella Therapeutics (Nasdaq: PVLA) announced dosing of first patients in the Phase 2 LOTU trial of QTORIN™ 3.9% rapamycin anhydrous gel for clinically significant angiokeratomas. The single-arm, baseline-controlled study will enroll up to 15 subjects (ages ≥6) at U.S. centers. Topline results are expected in the second half of 2027. QTORIN™ has FDA Fast Track designation and is formulated to target dermal mTOR-driven disease while minimizing systemic exposure. The study measures safety, tolerability, and multiple efficacy endpoints through Week 12.
Palvella Therapeutics (Nasdaq: PVLA) will report first quarter 2026 financial results before market open on Thursday, May 7, 2026. Management will host a conference call and webcast at 8:30 a.m. ET the same day to discuss results and provide a corporate update.
Investors can join the live webcast via the company’s Events & Presentations page or dial in at 800-715-9871 (domestic) or +1 646-307-1963 (international) using Conference ID 9970701. A replay will be archived for 90 days.
Palvella Therapeutics (Nasdaq: PVLA) announced that two late-breaking abstracts reporting results from the Phase 3 SELVA and Phase 2 TOIVA studies of QTORIN™ 3.9% rapamycin anhydrous gel were accepted for presentation at the ISSVA World Congress 2026.
Findings cited include statistically significant, clinically meaningful improvement in microcystic lymphatic malformations (SELVA) and cutaneous venous malformations (TOIVA). The presentations will occur during the late-breaking session on May 20, 2026 at 4:30 p.m. ET, presented by James Treat, MD. Slides will be available at the company website at the session start.
Palvella Therapeutics (Nasdaq: PVLA) appointed John D. Doux, M.D., M.B.A., to its Board of Directors effective April 13, 2026. Dr. Doux is a board-certified dermatologist, investor, and former Palvella director (2019–2022) with deep rare-skin-disease expertise and prior healthcare investment experience.
His background includes a 2015 Journal of Investigative Dermatology editorial advocating orphan-disease models in dermatology, roles at Palo Alto Investors since 2004, and board service at patient groups and biotech companies.
Palvella Therapeutics (Nasdaq: PVLA) appointed Kent Taylor as Senior Vice President of Sales, effective April 7, 2026. Taylor brings over 25 years of commercial experience and led launches for ZORYVE and OPZELURA. He will prepare Palvella’s U.S. sales organization for the potential launch of QTORIN™ rapamycin targeting microcystic lymphatic malformations, an area with no FDA-approved therapies and an estimated >30,000 diagnosed U.S. patients.
Palvella Therapeutics (Nasdaq: PVLA) reported full-year 2025 results and a corporate update on March 31, 2026. Key items: positive Phase 3 SELVA topline results for QTORIN™ rapamycin in microcystic LMs, NDA planning for 2H 2026, Phase 3 initiation for cutaneous VMs planned 2H 2026, new QTORIN™ pitavastatin program for DSAP, and an upsized equity raise resulting in pro forma cash ~$274M.
2025 financials: R&D $22.8M, G&A $15.8M, net loss $41.7M; cash and cash equivalents $58.0M as of Dec 31, 2025. Company intends a U.S. commercial launch readiness program.
Palvella Therapeutics (NASDAQ: PVLA) announced publication of a comprehensive review in Journal of Vascular Anomalies comparing microcystic and macrocystic lymphatic malformations and urging subtype-specific trial design and early treatment in children.
The paper highlights microcystic LMs as diffuse, treatment-resistant, and prone to infection, and supports the scientific rationale for QTORIN™ 3.9% rapamycin anhydrous gel, noting Phase 3 SELVA met its primary endpoint with statistically significant results and systemic rapamycin levels below 2 ng/mL.
Palvella Therapeutics (Nasdaq: PVLA) announced two poster presentations at the 2026 AAD annual meeting highlighting QTORIN™ rapamycin topical formulation science and a qualitative porokeratosis burden study.
Key details: QTORIN™ 3.9% rapamycin gel addresses crystallization and penetration issues; Phase 3 SELVA met its primary and all secondary endpoints (p<0.001) with systemic rapamycin <2ng/mL. A Phase 2 DSAP trial of QTORIN™ pitavastatin is anticipated in H2 2026.
Palvella Therapeutics (Nasdaq: PVLA) will report full year 2025 financial results before market open on Tuesday, March 31, 2026 and will host a conference call and corporate update at 8:30 a.m. ET the same day.
Investors can access a live webcast with slides via the company's Events & Presentations page; a replay will be available about two hours after the call and archived for 90 days.